Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan;61(1):88-94.
doi: 10.1002/mus.26739. Epub 2019 Nov 1.

Sural nerve sensory response in diabetic distal symmetrical polyneuropathy

Yun-Ru Lai  1   2   3 , Chih-Cheng Huang  3 , Wen-Chan Chiu  4 , Rue-Tsuan Liu  4 , Nai-Wen Tsai  3 , Hung-Chen Wang  5 , Wei-Che Lin  6 , Ben-Chung Cheng  1   4 , Yu-Jih Su  4 , Chih-Min Su  7 , Sheng-Yuan Hsiao  1   7 , Hsueh-Wen Chang  1 , Jung-Fu Chen  4 , Jih-Yang Ko  8 , Cheng-Hsien Lu  1   3   8   9
Affiliations

Sural nerve sensory response in diabetic distal symmetrical polyneuropathy

Yun-Ru Lai et al. Muscle Nerve. 2020 Jan.

Abstract

Introduction: The sural sensory nerve action potential (SNAP) amplitude is a measure of the number of axons. We tested the hypothesis that sural SNAP amplitude can be used as a marker in screening, severity evaluation, and follow-up of diabetic distal symmetrical polyneuropathy (DSPN).

Methods: Patients with type 2 diabetes underwent nerve conduction studies and were followed for 6 years. Composite amplitude scores (CASs) were determined to evaluate DSPN severity.

Results: Sural SNAP amplitudes were negatively correlated with CAS (r = -.790, P < .0001), and changes in sural SNAP amplitudes were negatively correlated with those of CAS after controlling for follow-up duration (r = -.531, P = .028).

Discussion: When a patient's baseline sural SNAP amplitude is above zero, it can be used as one measure of DSPN in screening, severity evaluation, and follow-up. However, if the patient's sural SNAP value is zero, CAS can be used as a follow-up measure.

Keywords: composite amplitudes score; diabetic distal symmetrical polyneuropathy; follow-up; screening; severity evaluation; sural sensory nerve action potential; type 2 diabetes.

PubMed Disclaimer

References

REFERENCES

    1. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A, KORA Study Group. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med. 2009;10:393-400.
    1. England JD, Gronseth GS, Franklin G, et al. Practice Parameter: Evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review): Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology. 2009;72:177-184.
    1. England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: a definition for clinical research Report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2005;64:199-207.
    1. Binns-Hall O, Selvarajah D, Sanger D, Walker J, Scott A, Tesfaye S. One-stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high-risk foot. Diabet Med. 2018;35:887-894.
    1. Veves A, Malik RA, Lye RH, et al. The relationship between sural nerve morphometric findings and measures of peripheral nerve function in mild diabetic neuropathy. Diabet Med. 1991;8:917-921.

Publication types

LinkOut - more resources